8-K: BridgeBio Reports Strong Q2 Attruby Sales, Key Trial Progress

BridgeBio Pharma announced robust second-quarter 2025 financial results, driven by accelerating Attruby sales and significant progress in multiple late-stage clinical trials for genetic diseases.

Summary

• Attruby has seen 3,751 unique patient prescriptions written by 1,074 unique prescribers as of August 1, 2025, indicating an accelerating launch with strong month-over-month growth in treatment-naive patients.
• Total second quarter revenue reached $110.6 million, comprising $71.5 million from U.S. Attruby net product revenue, $1.6 million from royalty revenue, and $37.5 million from license and services revenue.
• New analyses from the ATTRibute-CM study further strengthened Attruby's clinical profile, showing a 59% relative risk reduction for time to ACM or first CVH event in variant ATTR-CM patients versus placebo.
• A 31.6% relative risk reduction in mortality was associated with a 5-mg/dL increase in serum TTR within 28 days of treatment initiation through Month 30, linking early and increased TTR stabilization with improved clinical outcomes.
• Attruby also demonstrated a 43% reduction in annual frequency of CVH due to AF/AFL compared to placebo and a 17% reduction in the incidence of new-onset AF/AFL in the subgroup with no prior history of AF compared to placebo.
• Last participant last visit was achieved for FORTIFY, the registrational Phase 3 study of BBP-418 for LGMD2I/R9, with topline results expected in Fall 2025, supporting a potential NDA filing for Accelerated Approval in the U.S.
• Topline results from CALIBRATE, the registrational Phase 3 study of encaleret for ADH1, are also expected in Fall 2025, with approximately 95% of randomized study participants already having entered the long-term extension.
• PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia, expects topline results in early 2026; infigratinib previously received Breakthrough Therapy Designation from the FDA.
• The company ended the quarter with a strong cash, cash equivalents, and marketable securities balance of $756.9 million.
• Net loss attributable to common stockholders was $181.9 million for the three months ended June 30, 2025, and $349.3 million for the six months ended June 30, 2025.
• Net loss per share was $0.95 for the three months ended June 30, 2025, and $1.84 for the six months ended June 30, 2025.

Sentiment

Score: 8

Explanation: The filing presents a very positive outlook, driven by strong commercial performance of Attruby, significant progress in multiple late-stage clinical trials with promising data, and a robust cash position. While net loss increased, it is largely attributed to strategic investments in commercial launch and R&D, which are expected for a growing biopharma company. The pipeline advancements and potential for multiple first-in-class therapies are strong indicators of future growth.

Positives

• Accelerating Attruby launch with strong month-over-month growth in the crucial treatment-naive patient segment, reaching 3,751 unique patient prescriptions by 1,074 unique prescribers as of August 1, 2025.
• Significant increase in total second quarter revenue to $110.6 million, up from $2.2 million in the prior year, driven by robust U.S. Attruby net product revenue of $71.5 million.
• Attruby's differentiated clinical profile was further strengthened by new analyses from the ATTRibute-CM study, demonstrating a 59% relative risk reduction for time to ACM or first CVH event in variant ATTR-CM patients.
• New Attruby data showed a 31.6% relative risk reduction in mortality linked to early and increased TTR stabilization, and reductions in cardiovascular hospitalization due to AF/AFL (43%) and new-onset AF/AFL (17%).
• Last participant last visit achieved for FORTIFY (BBP-418 Phase 3 for LGMD2I/R9), with topline results expected in Fall 2025, supporting a potential Accelerated Approval.
• Topline results for CALIBRATE (encaleret Phase 3 for ADH1) are expected in Fall 2025, with high participant retention (95% entered long-term extension).
• Infigratinib for achondroplasia has previously demonstrated best-in-class improvements in annualized height velocity and upper-to-lower body proportionality and was granted Breakthrough Therapy Designation by the FDA.
• Strong cash, cash equivalents, and marketable securities balance of $756.9 million as of June 30, 2025, providing ample capital for ongoing operations and pipeline advancement.
• Received $300 million from the partial and capped sale of BEYONTTRA royalties to HealthCare Royalty and Blue Owl Capital.
• Received a $30 million regulatory-related milestone cash payment from Alexion for the Japan approval of BEYONTTRA.

Negatives

• Net loss attributable to common stockholders significantly increased to $181.9 million for Q2 2025 from $73.5 million for Q2 2024.
• Net loss per share increased to $0.95 for Q2 2025 from $0.39 for Q2 2024.
• Total operating costs and expenses increased by $67.1 million to $244.8 million for Q2 2025, primarily due to a $69.6 million increase in selling, general and administrative expenses reflecting investments in the Attruby commercial launch.
• Total other income (expense), net, decreased significantly to ($47.4) million for Q2 2025 from $100.0 million for Q2 2024, primarily due to a decrease in gain on deconsolidation of a subsidiary and an increase in interest expense.
• Net cash used in operating activities was $279.9 million for the first half of 2025.

Risks

• Initial and ongoing data from preclinical studies and clinical trials may not be indicative of final data.
• The potential size of the target patient populations for product candidates may not be as large as anticipated.
• The FDA or other regulatory agencies may not agree with regulatory approval strategies, components of filings (such as clinical trial designs, conduct, and methodologies), or the sufficiency of data submitted.
• The continuing success of collaborations is not guaranteed.
• The ability to obtain additional funding, including through less dilutive sources of capital than equity financings, is uncertain.
• Potential volatility in the company's share price.
• The impacts of current macroeconomic and geopolitical events, including hostilities in Ukraine and in Israel and the Gaza Strip, increasing rates of inflation, changing interest rates, and recently announced tariffs, could affect business operations and expectations.
• The company operates in a very competitive and rapidly changing environment where new risks emerge from time to time.

Future Outlook

The company expects the next six months to be transformative with Phase 3 readouts across ADH1, LGMD2I/R9, and achondroplasia, aiming to build on Attruby's success to become a leading diversified genetic disease company. They anticipate initiating clinical development for infigratinib in children from birth to less than 3 years old by the end of 2025 and a late-stage clinical study for encaleret in chronic hypoparathyroidism in 2026. Additionally, three new rare disease launches are expected in 2026 and 2027.

Management Comments

• "Attruby's latest results showcase the power of pairing breakthrough scientific excellence with disciplined commercial execution." Matt Outten, Chief Commercial Officer.
• "Product revenue nearly doubled this quarter, driven by growing adoption across centers of excellence and community physicians. With increasing demand and best-in-class patient access programs, we are confident Attruby will become the standard of care for ATTR-CM, setting the foundation for three additional rare disease launches in 2026 and 2027." Matt Outten, Chief Commercial Officer.
• "The launch of Attruby continues to accelerate, increasing the number of patients lives we are able to touch. We remain grateful for the physicians and patients who are partnering with us on both treatment and on new clinical research." Neil Kumar, Ph.D., CEO and Founder.
• "The next six months will be transformative with Phase 3 readouts across ADH1, LGMD2I/R9, and achondroplasia. We hope these programs will build on Attruby's success to allow us to become a leading diversified genetic disease company." Neil Kumar, Ph.D., CEO and Founder.

Industry Context

The company operates in the highly specialized and growing biopharmaceutical sector, with a strategic focus on genetic diseases. The accelerating commercial success of Attruby positions them as a significant player in the ATTR-CM market, a therapeutic area with increasing recognition and demand for effective treatments. Their robust pipeline, featuring multiple late-stage assets for LGMD2I/R9, ADH1, and achondroplasia, aligns with broader industry trends towards precision medicine and orphan drug development. The pursuit of 'first approved therapy' status for several indications underscores their ambition to address significant unmet medical needs and establish market leadership in underserved rare disease segments, reflecting a strong commitment to innovation in genetic medicine.

Comparison to Industry Standards

• Attruby's clinical profile, reinforced by new ATTRibute-CM study data (59% relative risk reduction for variant ATTR-CM, 31.6% mortality reduction linked to TTR stabilization, 43% reduction in CVH due to AF/AFL, 17% reduction in new-onset AF/AFL), positions it as a 'potentially best-in-class therapy' for ATTR-CM patients, suggesting strong competitive standing against existing treatments like Pfizer's Vyndaqel/Vyndamax (tafamidis) and Alnylam's RNAi therapies (Amvuttra, Onpattro).
• BBP-418 for LGMD2I/R9, if approved, would be the 'first approved therapy' for this condition, indicating a pioneering role in a disease with significant unmet medical need and no current approved treatments.
• Encaleret for ADH1, if successful, would be the 'first approved therapy' for this genetic form of hypoparathyroidism, highlighting its potential to address a previously unserved patient population.
• Infigratinib for achondroplasia has previously demonstrated 'best-in-class improvements in annualized height velocity and upper-to-lower body proportionality' compared to other FGFR inhibitors in development, such as BioMarin's Voxzogo (vosoritide), and if approved, would be the 'first approved oral therapy option' for achondroplasia and hypochondroplasia, offering a differentiated and potentially more convenient administration route.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong commercial performance of Attruby, positive clinical trial readouts, and a robust pipeline. Increased net loss and operating expenses are a short-term concern but are tied to growth investments.
• Patients: Significant positive impact through the accelerating launch of Attruby for ATTR-CM and the advancement of multiple potential first-in-class therapies for other rare genetic diseases (LGMD2I/R9, ADH1, achondroplasia, hypochondroplasia, chronic hypoparathyroidism).
• Healthcare Providers: Increased access to Attruby and potential future innovative treatments for rare genetic conditions, supported by strong clinical data.
• Employees: Continued investment in R&D and commercial activities suggests stable to growing employment opportunities within the company.
• Creditors: The company's strong cash position and successful capital raises (royalty sale, 2031 Notes issuance) enhance its financial stability and ability to meet obligations.

Next Steps

• Host quarterly earnings call and simultaneous webcast on August 5, 2025, at 4:30 pm ET.
• Share new rapidity of response data for Acoramidis at the ESC Congress in August 2025.
• Share more data on Attruby at additional medical meetings in the second half of 2025.
• Expect topline results from FORTIFY (BBP-418 Phase 3 study) in Fall 2025.
• Expect topline results from CALIBRATE (encaleret Phase 3 study) in Fall 2025.
• Expect enrollment completion for the Phase 2 portion of ACCEL 2/3 (infigratinib for hypochondroplasia) in the second half of 2025.
• Initiate clinical development for infigratinib in children with achondroplasia (birth to less than 3 years old) by the end of 2025.
• Expect topline results from PROPEL 3 (infigratinib Phase 3 study) in early 2026.
• Initiate a late-stage clinical study for encaleret for chronic hypoparathyroidism in 2026.
• Plan for three additional rare disease launches in 2026 and 2027.

Key Dates

Recommendation

The company demonstrates strong commercial execution with Attruby, which is rapidly gaining market traction and showing compelling clinical data reinforcing its best-in-class potential. The pipeline is robust, with multiple Phase 3 readouts expected in the near term for significant unmet needs in rare genetic diseases, offering multiple catalysts for value creation. While the net loss has increased, it is a result of strategic investments in commercialization and R&D, which are essential for long-term growth in the biopharmaceutical sector. The strong cash position provides ample runway to execute on these initiatives. The potential for multiple 'first approved therapies' positions the company for significant market leadership in these indications.

Keywords

Genetic diseases, Biopharmaceutical, ATTR-CM, Attruby, Acoramidis, LGMD2I/R9, BBP-418, ADH1, Encaleret, Achondroplasia, Infigratinib, Rare disease, Clinical trials, Phase 3, FDA approval, Commercial launch, Financial results, Orphan drug